Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017.

ABSTRACT:

Background

Direct oral anticoagulants (DOACs), namely rivaroxaban, apixaban, dabigatran, and edoxaban, are now included together with warfarin as standards of care for the primary treatment of venous thromboembolism (VTE). The extent to which the DOACs have been adopted since receiving US Food and Drug Administration (FDA) approval is unknown.

Objective

To document temporal trends in oral anticoagulant (OAC) prescriptions among anticoagulant-naïve patients initiating OACs for VTE primary treatment in the United States and to report participant characteristics by OAC prescribed for the year 2017.

Methods

MarketScan databases for years 2012 through 2017 were used to identify VTE cases and comorbidities using International Classification of Diseases codes and pres

SUBMITTER: Lutsey PL 

PROVIDER: S-EPMC6782014 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature